home / stock / hccc / hccc quote
Last: | $0.15 |
---|---|
Change Percent: | -40.0% |
Open: | $0.25 |
Close: | $0.15 |
High: | $0.25 |
Low: | $0.15 |
Volume: | 6,667 |
Last Trade Date Time: | 10/05/2020 04:44:07 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.15 | $0.25 | $0.15 | $0.25 | $0.15 | 6,667 | 10-05-2020 |
$0.3 | $0.3 | $0.3 | $0.3 | $0.3 | 1,770 | 10-01-2020 |
$0.3 | $0.3 | $0.3 | $0.3 | $0.298 | 6,070 | 09-30-2020 |
$0.28 | $0.28 | $0.28 | $0.28 | $0.28 | 425 | 09-24-2020 |
$0.21 | $0.21 | $0.21 | $0.21 | $0.21 | 4,800 | 09-22-2020 |
$0.288 | $0.288 | $0.288 | $0.288 | $0.288 | 250 | 09-21-2020 |
$0.247 | $0.254 | $0.247 | $0.258 | $0.238 | 8,190 | 09-18-2020 |
$0.2 | $0.11 | $0.2 | $0.2 | $0.11 | 16,574 | 09-16-2020 |
$0.122 | $0.122 | $0.122 | $0.122 | $0.122 | 2,000 | 09-15-2020 |
$0.1175 | $0.2 | $0.1175 | $0.2 | $0.1175 | 530 | 09-10-2020 |
$0.17 | $0.145 | $0.17 | $0.17 | $0.143 | 23,328 | 09-08-2020 |
$0.15 | $0.188 | $0.15 | $0.188 | $0.15 | 43,421 | 09-07-2020 |
$0.15 | $0.188 | $0.15 | $0.188 | $0.15 | 43,421 | 09-04-2020 |
$0.202 | $0.202 | $0.202 | $0.202 | $0.202 | 514 | 08-28-2020 |
$0.202 | $0.21 | $0.202 | $0.21 | $0.202 | 1,000 | 08-26-2020 |
$0.202 | $0.265 | $0.202 | $0.265 | $0.202 | 3,514 | 08-25-2020 |
$0.27 | $0.27 | $0.27 | $0.27 | $0.27 | 1,250 | 08-24-2020 |
$0.27 | $0.27 | $0.27 | $0.27 | $0.27 | 518 | 08-21-2020 |
$0.202 | $0.202 | $0.202 | $0.202 | $0.202 | 150 | 08-18-2020 |
$0.27 | $0.203 | $0.27 | $0.27 | $0.203 | 3,250 | 08-13-2020 |
News, Short Squeeze, Breakout and More Instantly...
H/Cell Energy Corp Company Name:
HCCC Stock Symbol:
OTCMKTS Market:
The pooled analysis included data from 4 i nternational clinical trials spanning a n array of hard-to-treat indications including skin, head & neck, and oral cavity. Initial response data demonstrated an overall response rate of almost 100% in tre...
JERUSALEM, May 21, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced that CFO Raphi Levy will present a corporate overview an...
- Presented preclinical data demonstrating abscopal immune effect in pancreatic murine tumor models at ESTRO 2024 Congress in Glasgow - - First patient with liver metastases treated in a feasibility and safety study of Alpha DaRT at the McGill University Health Center in Montreal, C...